Skip to main content

Table 1 Patient, disease, and transplant characteristics according to donor type

From: Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Characteristics

Total

N = 469

MSD

N = 78

MUD

N = 94

Haplo

N = 297

p

Age in years, median (range)

37 (18–75)

37 (18–67)

33 (18–75)

39 (18–75)

0.2

Gender, n (%)

    

1

 Male

299 (64)

50 (64)

60 (65)

189 (64)

 

 Female

170 (36)

28 (36)

34 (35)

108 (36)

 

Karnofsky performance status, n (%)

    

0.4

 ≥ 90

352 (78)

53 (73)

67 (76)

232 (80)

 

 < 90

99 (22)

20 (27)

21 (24)

58 (20)

 

 Missing

18

5

6

7

 

Cell lineage, n (%)

    

0.7

 B-cell

359 (77)

57 (73)

73 (78)

229 (77)

 

 T-cell

110 (23)

21 (27)

21 (22)

68 (23)

 

Ph-chromosome status, n (%)

     

 Negative

243 (59)

43 (64)

53 (61)

147 (58)

0.6

 Positive

166 (41)

24 (36)

34 (39)

108 (42)

 

 Missing

60

11

7

42

 

Months from diagnosis to transplant, median (range)

6 (1–18)

6 (1–18)

7 (3–18)

6 (1–18)

0.2

Conditioning intensity, n (%)

    

0.5

 Myeloablative

387 (83)

63 (83)

82 (83)

242 (82)

 

 Reduced intensity

79 (17)

13 (17)

12 (17)

54 (18)

 

 Missing

3

2

0

1

 

Type of conditioning, n (%)

    

0.6

 Based on chemotherapy

259 (55)

40 (52)

56 (60)

163 (55)

 

 Based on TBI

209 (45)

37 (48)

36 (40)

134 (45)

 

 Missing

1

1

0

0

 

Stem cell source, n (%)

    

< 0.001

 Bone marrow

176 (38)

20 (26)

11 (12)

145 (49)

 

 Mobilized peripheral blood

293 (62)

58 (74)

83 (88)

152 (51)

 

In vivo T-cell depletion, n (%)

58 (12)

13 (17)

22 (23)

23 (8)

 < 0.001

GvHD prophylaxis, n (%)

    

 < 0.001

 PTCy + 2 drugs

367 (78)

25 (32)

69 (73)

273 (92)

 

 PTCy + 1 drug

75 (16)

32 (41)

21 (22)

22 (7)

 

 PTCy only

27 (6)

21 (27)

4 (4)

2 (1)

 

Donor–recipient gender combination, n (%)

    

0.08

 Female donor to male recipient

118 (25)

27 (35)

19 (20)

72 (24)

 

 Other combinations

350 (75)

51 (65)

74 (80)

225 (76)

 

 Missing

1

0

1

0

 

Donor–recipient CMV serostatus, n (%)

    

< 0.001

 Negative–negative

63 (14)

10 (14)

23 (26)

30 (11)

 

 Positive–negative

46 (10)

11 (15)

11 (12)

24 (8)

 

 Negative–positive

65 (15)

6 (8)

23 (26)

36 (13)

 

 Positive–positive

275 (61)

46 (63)

33 (37)

196 (69)

 

 Missing

20

5

4

11

 

Year of transplant, median (range)

2016 (2010–2018)

2016 (2010–2018)

2016 (2010–2018)

2016 (2011–2018)

0.8

  1. MSD, matched sibling donor; MUD, matched unrelated donor; Haplo, haploidentical donor; ALL, acute lymphoblastic leukemia; Ph, Philadelphia chromosome; TBI, total body irradiation; GvHD, graft-versus-host disease; PTCy, post-transplant cyclophosphamide; CMV, cytomegalovirus; p, p value
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us